QGEN — QIAGEN N.V.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1015820 ·
Netherlands
Last close
$49.75
Market Cap
$10.27B
52W High
$57.30
52W Low
$32.24
ADV30
5,047,125
Next earnings
2027-02-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 547,869,000 | 354,000,000 | 151,643,000 | 105,659,000 | 5,942,470,000 | 805,132,000 | 2,467,508,000 |
| Jun 2026 | 535,040,000 | 340,386,000 | 140,850,000 | 103,401,000 | 5,889,202,000 | 768,500,000 | 2,531,462,000 |
| Mar 2026 | 492,320,000 | 309,603,000 | 116,626,000 | 68,043,000 | 5,782,065,000 | 646,289,000 | 2,450,359,000 |
| Dec 2025 | 540,420,000 | 325,269,000 | 121,880,000 | 107,829,000 | 6,281,232,000 | 839,005,000 | 2,503,078,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$654,470,000
Investing CF
$-242,149,000
Financing CF
$-376,407,000
CapEx
$-213,873,000
Dividends Paid
$1,000
Buybacks
$0
EPS Diluted TTM
$1.98
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$2,814,982,000
Inventory
$311,355,000
Receivables
$389,850,000
ST Investments
$25,000,000
EBIT TTM
$501,259,000
Pretax Income TTM
$461,829,000
Interest Exp TTM
$39,430,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,100,363,008
EBITDA
$734,185,024
Free Cash Flow
$372,855,136
Enterprise Value
$9,636,236,288
Total Cash
$793,500,032
Total Debt
$1,653,698,944
Shares Out
206,495,000
Trailing EPS
$1.97
Book Value
$16.26
ROE
11.9%
ROA
5.9%
Div Yield
0.83%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,089,999,000 | 520,310,000 | 424,880,000 | 6,281,232,000 | 2,503,078,000 | 3,778,154,000 | 654,326,000 |
| Dec 2024 | 1,978,214,000 | 199,899,000 | 83,591,000 | 5,689,622,000 | 2,122,283,000 | 3,567,339,000 | 673,551,000 |
| Dec 2023 | 1,965,311,000 | 445,247,000 | 341,303,000 | 6,115,190,000 | 2,307,426,000 | 3,807,764,000 | 459,455,000 |
| Dec 2022 | 2,141,518,000 | 576,228,000 | 423,211,000 | 6,287,735,000 | 2,821,124,000 | 3,466,611,000 | 715,264,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.61
Max Pain — expiry 2026-12-18
max pain strike: $45.00 · spot: $49.56 · call oi: 14,546 · put oi: 3,245
Expected Move to 2026-12-18:
±$0.88
(1.77%) —
implied range
$48.69 –
$50.44
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGEN | REPLIGEN CORP | $10.30B | $162.18 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.37B | $121.52 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $10.94B | $95.97 | — |
| PCVX | Vaxcyte, Inc. | $9.40B | $59.40 | — |
| TECH | BIO-TECHNE Corp | $11.41B | $72.63 | — |
News headlines (Yahoo Finance, 1h cache)
Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen
2026-11-12 15:00 · Yahoo
RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics
2026-11-12 14:06 · Yahoo
Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate
2026-11-11 14:21 · Yahoo
Human Identification - Global Strategic Business Report 2026: Capitalize on 10.1% CAGR to $1.9 Billion by 2032 | Thermo Fisher, Illumina, Qiagen and Bio-Rad Vie for Shares
2026-11-11 14:15 · Yahoo
Epigenetics - Global Strategic Business Report: Capitalize on an 18.2% CAGR to Secure the $5.5 Billion 2030 Market as Illumina, Thermo Fisher Scientific, Qiagen, and Bio-Rad Disrupt Precision Medicine
2026-11-11 14:12 · Yahoo
Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director
2026-11-11 12:17 · Yahoo
Electrophoresis Reagents - Global Strategic Business Report: Capitalize on China's 7.4% CAGR as Bio-Rad, QIAGEN, Agilent, Merck Millipore and Thermo Fisher Battle for $1.3B by 2032
2026-11-10 15:09 · Yahoo
Nucleic Acid Isolation and Purification - Global Strategic Business Report: Capture the $3.9 Billion Revenue Surge by 2030 as Thermo Fisher, Qiagen, Danaher, Illumina, and Bio-Rad Battle for Share
2026-11-10 15:02 · Yahoo
Gene Panels - Global Strategic Business Report 2026: Capitalize on 17.9% CAGR as Market Triples to $12.6B by 2032 - Track Key Players Illumina, Roche, QIAGEN, Thermo Fisher, Agilent and More
2026-11-10 14:24 · Yahoo
Personalized Medicines - Global Strategic Business Report 2026: Capitalize on the $496.6B Market by 2032 | Competitive Intelligence on Roche, Novartis, Abbott Molecular and QIAGEN
2026-11-10 14:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.